Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 87 of the 91 references it cites were found in a registry or an index; 16 of the 43 sources its claims cite were checked for support.

Genetic and Functional Analyses of SHANK2 Mutations Suggest a Multiple Hit Model of Autism Spectrum Disorders

Open access

Abstract

Autism spectrum disorders (ASD) are a heterogeneous group of neurodevelopmental disorders with a complex inheritance pattern. While many rare variants in synaptic proteins have been identified in patients with ASD, little is known about their effects at the synapse and their interactions with other genetic variations. Here, following the discovery of two de novo SHANK2 deletions by the Autism Genome Project, we identified a novel 421 kb de novo SHANK2 deletion in a patient with autism. We then sequenced SHANK2 in 455 patients with ASD and 431 controls and integrated these results with those reported by Berkel et al. 2010 (n = 396 patients and n = 659 controls). We observed a significant enrichment of variants affecting conserved amino acids in 29 of 851 (3.4%) patients and in 16 of 1,090 (1.5%) controls (P = 0.004, OR = 2.37, 95% CI = 1.23-4.70). In neuronal cell cultures, the variants identified in patients were associated with a reduced synaptic density at dendrites compared to the variants only detected in controls (P = 0.0013). Interestingly, the three patients with de novo SHANK2 deletions also carried inherited CNVs at 15q11-q13 previously associated with neuropsychiatric disorders. In two cases, the nicotinic receptor CHRNA7 was duplicated and in one case the synaptic translation repressor CYFIP1 was deleted. These results strengthen the role of synaptic gene dysfunction in ASD but also highlight the presence of putative modifier genes, which is in keeping with the "multiple hit model" for ASD. A better knowledge of these genetic interactions will be necessary to understand the complex inheritance pattern of ASD.

Overview

CoChat Summary

TL;DR

This study identifies a novel de novo SHANK2 deletion and finds enrichment of conserved SHANK2 variants in ASD, with patient variants reducing synaptic density in vitro. It also reports inherited 15q11–q13 CNVs in all three patients with de novo SHANK2 deletions, supporting a multiple-hit model.

Key findings

  • A novel 421.2 kb de novo SHANK2 deletion was found in patient AU038_3 with autism and moderate ID; it covered 12 exons (E5–E16), altered all SHANK2 isoforms, was absent from parents, originated on the maternal chromosome, and was absent in more than 5000 controls and the Database of Genomic Variants.
  • SHANK2 variants affecting conserved amino acids were enriched in ASD: 29 of 851 (3.4%) patients versus 16 of 1090 (1.5%) controls (Fisher’s exact test 1-sided, P = 0.004, OR = 2.37, 95% CI = 1.23–4.70).
  • In cultured neurons, 8 variants reduced Shank2-positive synapse density; after Bonferroni correction, 4 remained significant (A729T, G1170R, L1722P identified only in patients; S557N observed more frequently in patients). Patient variants were associated with lower synaptic density than variants shared by patients and controls (P = 0.022) or detected only in controls (P = 0.0013).
  • All three patients with de novo SHANK2 deletions also carried inherited 15q11–q13 CNVs: two had a 496 kb CHRNA7 duplication, and one had a 468 kb BP1–BP2 deletion removing NIPA1, NIPA2, CYFIP1, and TUBGCP5.

Methods

  • CNV analysis used Illumina 1M Duo SNP arrays in 260 patients with ASD; mutation screening sequenced SHANK2E in 230 patients and 230 controls and ProSAP1A in an additional 225 patients and 201 controls, integrated with Berkel et al. 2010 (396 patients and 659 controls); enrichment was tested with 1-sided Fisher’s exact tests.
  • Functional assays introduced 16 variants from the first screen into rat GFP-ProSAP1A/Shank2A cDNA, transfected primary rat hippocampal neurons, and quantified Shank2-positive synapses per 10 µm dendrite using Mann-Whitney U tests and Student’s t tests.
  • CNV burden was analyzed in the three patients with de novo SHANK2 deletions and in the control carrying the SHANK2 splice mutation, using the study’s 260 patients/290 controls and the Autism Genome Project dataset of 996 patients/1287 controls, with 2-sided Fisher’s exact tests.

Limitations

  • The paper states that the in vitro assays show variants can potentially impact protein function but do not confirm deleterious effects on neuronal function in vivo in people carrying them; parents were apparently asymptomatic, so the causative role of inherited variants remains difficult to ascertain.
  • The paper states that the epistasis findings are based on small numbers and that, from a single control subject, it cannot formally prove that additional hits at SNTG2 and/or MYT1L acted as suppressor mutations.
  • Evident from the text: the functional work relies on overexpression in cultured neurons rather than endogenous or in vivo models, and several co-occurring CNV comparisons were not statistically significant (e.g., CHRNA7 duplication P = 0.19; ARHGAP11B deletion P = 0.15; BP1–BP2 deletion P = 0.74), so the multiple-hit interpretation rests on small patient counts.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1002521

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Genomic structure, isoforms, and expression of human SHANK2. A. Genomic structure of the human SHANK2 gene. Transcription of SHANK2 produces four main mRNA from three distinct promoters: SHANK2E (AB208025), ProSAP1A (AB208026), ProSAP1 (AB208027) and AF141901. There are three translation starts: in exon 2 for SHANK2E, in exon1b for ProSAP1A, and in exon1c for ProSAP1 and AF141901; and two independent stop codons: in exon 22b for AF141901 and in exon 25 for SHANK2E, ProSAP1A and ProSAP1. Conserved domains of protein interaction or protein binding site are represented in color: ANK (red), SH3 (orange), PDZ (blue) and SAM (green), H (pink), D, (dark blue) and C (purple). Black stars identify the alternative spliced exons (‘brain-specific exons’ in turquoise: 19, 20 and 23). B. RT-PCRs of SHANK2 isoforms on RNA from different human control tissues (Clontech), and different brain regions of four controls (2 males and 2 females). The amplified regions specific to each isoform of SHANK2 are indicated by gray boxes. C. Alternative splicing of human SHANK2; exons 19, 20 and 23 are specific to the brain. ANK, ankyrin; SH3, Src homology 3; PDZ, PSD95/DLG/ZO1; SAM, sterile alpha motif; He, heart; Li, liver; B, brain; SM, skeletal muscle; Pl, placenta; K, kidney; Lu, lung; Pa, pancreas; FC, frontal cortex; Hi, hippocampus; TC, temporal cortex; T, thalamus; OC, occipital cortex; Ce, cerebellum; Cx, whole cortex; BLCL, B lymphoblastoid cell lines; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; BSR, brain specific region; H, homer binding site; D, dynamin binding site; C, cortactin binding site. The ages of the two males and the two females studied were 74, 42, 55, and 36 years with a post-mortem interval of 10, 21, 24, and 2 h, respectively.
Figure 1 Genomic structure, isoforms, and expression of human SHANK2. A. Genomic structure of the human SHANK2 gene. Transcription of SHANK2 produces four main mRNA from three distinct promoters: SHANK2E (AB208025), ProSAP1A (AB208026), ProSAP1 (AB208027) and AF141901. There are three translation starts: in exon 2 for SHANK2E, in exon1b for ProSAP1A, and in exon1c for ProSAP1 and AF141901; and two independent stop codons: in exon 22b for AF141901 and in exon 25 for SHANK2E, ProSAP1A and ProSAP1. Conserved domains of protein interaction or protein binding site are represented in color: ANK (red), SH3 (orange), PDZ (blue) and SAM (green), H (pink), D, (dark blue) and C (purple). Black stars identify the alternative spliced exons (‘brain-specific exons’ in turquoise: 19, 20 and 23). B. RT-PCRs of SHANK2 isoforms on RNA from different human control tissues (Clontech), and different brain regions of four controls (2 males and 2 females). The amplified regions specific to each isoform of SHANK2 are indicated by gray boxes. C. Alternative splicing of human SHANK2; exons 19, 20 and 23 are specific to the brain. ANK, ankyrin; SH3, Src homology 3; PDZ, PSD95/DLG/ZO1; SAM, sterile alpha motif; He, heart; Li, liver; B, brain; SM, skeletal muscle; Pl, placenta; K, kidney; Lu, lung; Pa, pancreas; FC, frontal cortex; Hi, hippocampus; TC, temporal cortex; T, thalamus; OC, occipital cortex; Ce, cerebellum; Cx, whole cortex; BLCL, B lymphoblastoid cell lines; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; BSR, brain specific region; H, homer binding site; D, dynamin binding site; C, cortactin binding site. The ages of the two males and the two females studied were 74, 42, 55, and 36 years with a post-mortem interval of 10, 21, 24, and 2 h, respectively.CC BY · PubMed Central
Figure 2 SHANK2 mutations in patients with ASD. A. A heterozygous deletion of SHANK2 was identified with the Illumina Human 1M-Duo SNP array in a patient with autism (AU038_3). The deletion spans 421 kb on chromosome 11q13.3, covers twelve exons of the human SHANK2 and is not present in the parents. Each dot shows Log R Ratio (LRR; in red) and B allele frequency (BAF; in green). QuantiSNP score is represented with a blue line and indicates the deletion size. B. Location of the CNV and sequence variants (from this study and Berkel et al. 2010) along the SHANK2 protein: in red the variations specific to ASD, in orange the variations shared by ASD and controls and in green the variations specific to controls [26]. The breakpoints of the SHANK2 deletion in AU038_3 are represented with a dotted line on the protein. Stars indicate the variants affecting conserved amino acids. C. A total of 40 variants were identified and variants affecting conserved amino acids in other SHANK proteins are enriched in patients with ASD (nconserved = 12 and nnon-conserved = 3) compared with controls (nconserved = 6 and nnon-conserved = 11) (Fisher's exact test 1-sided, P = 0.013, OR = 6.83, 95% IC = 1.19–53.40). D. The percentage of carriers of SHANK2 variants in patients with ASD and Controls. Variants affecting a conserved amino acid among the SHANK proteins are enriched in patients with ASD (nconserved = 29 and nnon-conserved = 822) compared with controls (nconserved = 16 and nnon-conserved = 1074) (Fisher's exact test 1-sided, P = 0.004, OR = 2.37, 95% CI = 1.23–4.70). Open squares and filled squares represent the non-conserved and conserved amino acids, respectively. ANK, Ankyrin repeat domain; SH3, Src homology 3 domain; PDZ, postsynaptic density 95/Discs large/zona occludens-1 homology domain; SAM, sterile alpha motif domain; BSR, brain specific region; H, homer binding site; D, dynamin binding site; C, cortactin binding site. The proline-rich region is represented as a horizontal gray line.
Figure 2 SHANK2 mutations in patients with ASD. A. A heterozygous deletion of SHANK2 was identified with the Illumina Human 1M-Duo SNP array in a patient with autism (AU038_3). The deletion spans 421 kb on chromosome 11q13.3, covers twelve exons of the human SHANK2 and is not present in the parents. Each dot shows Log R Ratio (LRR; in red) and B allele frequency (BAF; in green). QuantiSNP score is represented with a blue line and indicates the deletion size. B. Location of the CNV and sequence variants (from this study and Berkel et al. 2010) along the SHANK2 protein: in red the variations specific to ASD, in orange the variations shared by ASD and controls and in green the variations specific to controls [26]. The breakpoints of the SHANK2 deletion in AU038_3 are represented with a dotted line on the protein. Stars indicate the variants affecting conserved amino acids. C. A total of 40 variants were identified and variants affecting conserved amino acids in other SHANK proteins are enriched in patients with ASD (nconserved = 12 and nnon-conserved = 3) compared with controls (nconserved = 6 and nnon-conserved = 11) (Fisher's exact test 1-sided, P = 0.013, OR = 6.83, 95% IC = 1.19–53.40). D. The percentage of carriers of SHANK2 variants in patients with ASD and Controls. Variants affecting a conserved amino acid among the SHANK proteins are enriched in patients with ASD (nconserved = 29 and nnon-conserved = 822) compared with controls (nconserved = 16 and nnon-conserved = 1074) (Fisher's exact test 1-sided, P = 0.004, OR = 2.37, 95% CI = 1.23–4.70). Open squares and filled squares represent the non-conserved and conserved amino acids, respectively. ANK, Ankyrin repeat domain; SH3, Src homology 3 domain; PDZ, postsynaptic density 95/Discs large/zona occludens-1 homology domain; SAM, sterile alpha motif domain; BSR, brain specific region; H, homer binding site; D, dynamin binding site; C, cortactin binding site. The proline-rich region is represented as a horizontal gray line.CC BY · PubMed Central
Figure 3 Genetic alterations identified in the control subject SWE_Q56_508. A. SHANK2 splice mutation (IVS22+1G>T) detected in a Swedish female control, SWE_Q56_508. The mutation altered the donor splicing site of exon 22 and led to a premature stop in all SHANK2 isoforms except for the AF1411901 isoform, where it altered the protein sequence (G263V). B. CNVs in the same individual altering LOC339822, SNTG2, PXDN and MYT1L. The two close duplications span 264 kb and 245 kb on chromosome 2 and altered LOC339822 and SNTG2, and PXDN and MYT1L, respectively. Dots show the B allele frequency (BAF; in green), Log R ratio (LRR; in red), and QuantiSNP score (in blue). Lower panel: all CNVs listed in the Database of Genomic Variants (DGV) are represented: loss (in red), gain (in blue), gain or loss (in brown). H, homer binding site; D, dynamin binding site; C, cortactin binding site.
Figure 3 Genetic alterations identified in the control subject SWE_Q56_508. A. SHANK2 splice mutation (IVS22+1G>T) detected in a Swedish female control, SWE_Q56_508. The mutation altered the donor splicing site of exon 22 and led to a premature stop in all SHANK2 isoforms except for the AF1411901 isoform, where it altered the protein sequence (G263V). B. CNVs in the same individual altering LOC339822, SNTG2, PXDN and MYT1L. The two close duplications span 264 kb and 245 kb on chromosome 2 and altered LOC339822 and SNTG2, and PXDN and MYT1L, respectively. Dots show the B allele frequency (BAF; in green), Log R ratio (LRR; in red), and QuantiSNP score (in blue). Lower panel: all CNVs listed in the Database of Genomic Variants (DGV) are represented: loss (in red), gain (in blue), gain or loss (in brown). H, homer binding site; D, dynamin binding site; C, cortactin binding site.CC BY · PubMed Central
Figure 4 Characterization of the functional impact of SHANK2 mutations in cultured neuronal cells. A. The colocalization of ProSAP1A/SHANK2-EGFP (postsynaptic marker) and Bassoon (presynaptic marker) indicated that the mutations did not disturb the formation of SHANK2 clusters at excitatory synapses along the dendrites. B. The quantification of synapse density was performed on 20 transfected hippocampal neurons per construct from at least three independent experiments. The majority of the ProSAP1A variants affecting a conserved amino acid among SHANK proteins reduced significantly the synaptic density compared with the variants that affect amino acid non conserved among SHANK proteins (Mann-Whitney U-test: nWT = 20, nmut = 20; US557N = 82.5, pS557N = 0.001; UR569H = 124, pR569H = 0.04; UL629P = 149, pL629P = 0.17; UV717F = 114, pV717F = 0.02; UA729T = 73, pA729T = 0.000; UK780Q = 154, pK780Q = 0.221; UR818H = 108, pR818H = 0.012; UA822T = 154.5, pA822T = 0.224; UV823M = 129, pV823M = 0.056; UY967C = 134, pY967C = 0.076; UG1170R = 78, pG1170R = 0.001; UR1290W = 142, pR1290W = 0.121; UQ1308R = 162, pQ1308R = 0.314; UD1535N = 97, pD1535N = 0.005; UP1586L = 137, pP1586L = 0.910; UL1722P = 79, pL1722P = 0.001, *p<0.05, **p<0.01, ***p<0.001). C. Effect of the variants on synaptic density. The y-axis represents −log P compared to WT (P obtained with Mann-Whitney test). After Bonferroni correction for 16 tests, only P values<0.003 were considered as significant. Variants represented in red were specific to ASD, in orange were shared by ASD and controls, and in green were specific to the controls. Open circles and filled circles represent non conserved and conserved amino acids, respectively. Prim, primary; second, secondary.
Figure 4 Characterization of the functional impact of SHANK2 mutations in cultured neuronal cells. A. The colocalization of ProSAP1A/SHANK2-EGFP (postsynaptic marker) and Bassoon (presynaptic marker) indicated that the mutations did not disturb the formation of SHANK2 clusters at excitatory synapses along the dendrites. B. The quantification of synapse density was performed on 20 transfected hippocampal neurons per construct from at least three independent experiments. The majority of the ProSAP1A variants affecting a conserved amino acid among SHANK proteins reduced significantly the synaptic density compared with the variants that affect amino acid non conserved among SHANK proteins (Mann-Whitney U-test: nWT = 20, nmut = 20; US557N = 82.5, pS557N = 0.001; UR569H = 124, pR569H = 0.04; UL629P = 149, pL629P = 0.17; UV717F = 114, pV717F = 0.02; UA729T = 73, pA729T = 0.000; UK780Q = 154, pK780Q = 0.221; UR818H = 108, pR818H = 0.012; UA822T = 154.5, pA822T = 0.224; UV823M = 129, pV823M = 0.056; UY967C = 134, pY967C = 0.076; UG1170R = 78, pG1170R = 0.001; UR1290W = 142, pR1290W = 0.121; UQ1308R = 162, pQ1308R = 0.314; UD1535N = 97, pD1535N = 0.005; UP1586L = 137, pP1586L = 0.910; UL1722P = 79, pL1722P = 0.001, *p<0.05, **p<0.01, ***p<0.001). C. Effect of the variants on synaptic density. The y-axis represents −log P compared to WT (P obtained with Mann-Whitney test). After Bonferroni correction for 16 tests, only P values<0.003 were considered as significant. Variants represented in red were specific to ASD, in orange were shared by ASD and controls, and in green were specific to the controls. Open circles and filled circles represent non conserved and conserved amino acids, respectively. Prim, primary; second, secondary.CC BY · PubMed Central
Figure 5 Characterization of CNVs in three patients carrying a de novo deletion of SHANK2. Paternally or maternally inherited CNVs are indicated by squares and circles, respectively. De novo CNVs are indicated by stars. Deletions and duplications are indicated in red and blue, respectively. CNVs hitting exons or only introns are filled with grey and white, respectively. Squares and circles within star represent de novo CNV of paternal or maternal origin; circles within squares represent CNV inherited by father or mother. ABCC6, ATP-binding cassette, sub-family C, member 6 pseudogene 2; ADAM, ADAM metallopeptidase; AMY1, amylase (salivary); AMY2A, amylase (pancreatic); ARHGAP11B, Rho GTPase activating protein 11B; CAMSAP1L1, calmodulin regulated spectrin-associated protein 1-like 1; CHRNA7, cholinergic receptor, nicotinic, alpha 7; CNTN4, contactin 4; CTNNA3, catenin (cadherin-associated protein), alpha 3; CYFIP1, cytoplasmic FMR1 interacting protein 1; DUSP22, dual specificity phosphatase 22; GALM, galactose mutarotase; GCNT2, glucosaminyl (N-acetyl) transferase 2; GOLGA, golgi autoantigen, golgin subfamily a; GSTT1, glutathione S-transferase theta 1; HLA-DRB, major histocompatibility complex, class II, DR beta; LAMA4, laminin, alpha 4; NIPA, non imprinted in Prader-Willi/Angelman syndrome; NLGN1, neuroligin 1; NME7, non-metastatic cells 7; OR, olfactory receptor; PCDHA, protocadherin alpha; RFPL4B, ret finger protein-like 4B; RHD, Rh blood group, D antigen; SFMBT1, Scm-like with four mbt domains 1; SHANK2, SH3 and multiple ankyrin repeat domains 2; SMC2, structural maintenance of chromosomes 2; TNS3, tensin 3; TUBGCP5, tubulin, gamma complex associated protein 5; UGT2B17, UDP glucuronosyltransferase 2 family, polypeptide B17.
Figure 5 Characterization of CNVs in three patients carrying a de novo deletion of SHANK2. Paternally or maternally inherited CNVs are indicated by squares and circles, respectively. De novo CNVs are indicated by stars. Deletions and duplications are indicated in red and blue, respectively. CNVs hitting exons or only introns are filled with grey and white, respectively. Squares and circles within star represent de novo CNV of paternal or maternal origin; circles within squares represent CNV inherited by father or mother. ABCC6, ATP-binding cassette, sub-family C, member 6 pseudogene 2; ADAM, ADAM metallopeptidase; AMY1, amylase (salivary); AMY2A, amylase (pancreatic); ARHGAP11B, Rho GTPase activating protein 11B; CAMSAP1L1, calmodulin regulated spectrin-associated protein 1-like 1; CHRNA7, cholinergic receptor, nicotinic, alpha 7; CNTN4, contactin 4; CTNNA3, catenin (cadherin-associated protein), alpha 3; CYFIP1, cytoplasmic FMR1 interacting protein 1; DUSP22, dual specificity phosphatase 22; GALM, galactose mutarotase; GCNT2, glucosaminyl (N-acetyl) transferase 2; GOLGA, golgi autoantigen, golgin subfamily a; GSTT1, glutathione S-transferase theta 1; HLA-DRB, major histocompatibility complex, class II, DR beta; LAMA4, laminin, alpha 4; NIPA, non imprinted in Prader-Willi/Angelman syndrome; NLGN1, neuroligin 1; NME7, non-metastatic cells 7; OR, olfactory receptor; PCDHA, protocadherin alpha; RFPL4B, ret finger protein-like 4B; RHD, Rh blood group, D antigen; SFMBT1, Scm-like with four mbt domains 1; SHANK2, SH3 and multiple ankyrin repeat domains 2; SMC2, structural maintenance of chromosomes 2; TNS3, tensin 3; TUBGCP5, tubulin, gamma complex associated protein 5; UGT2B17, UDP glucuronosyltransferase 2 family, polypeptide B17.CC BY · PubMed Central
Figure 6 Inherited 15q11–q13 CNVs identified in three ASD patients carrier of a de novo SHANK2 deletion. Deletions (del) and duplications (dup) are indicated in red and blue, respectively. Paternally and maternally imprinted genes are indicated in yellow and pink, respectively. Genes altered by the CNVs are indicated in blue or red. The bottom part of the figure indicates the location of the deletions/duplications previously associated with neuropsychiatric disorders [43]–[61]. BP, breakpoint; Inh_M, inherited by mother; Inh_F, inherited by father; AS, Angelman syndrome; ASD, Autism spectrum disorders; ADHD, attention deficit-hyperactivity disorder; BP, bipolar disorder; DD: developmental delay; DBD, disruptive behavior disorder; EPI, epilepsy; GAD, generalized anxiety disorder; OCD, obsessive-compulsive disorder; ID, intellectual disability; PWS, Prader-Willi syndrome; SCZ, schizophrenia.
Figure 6 Inherited 15q11–q13 CNVs identified in three ASD patients carrier of a de novo SHANK2 deletion. Deletions (del) and duplications (dup) are indicated in red and blue, respectively. Paternally and maternally imprinted genes are indicated in yellow and pink, respectively. Genes altered by the CNVs are indicated in blue or red. The bottom part of the figure indicates the location of the deletions/duplications previously associated with neuropsychiatric disorders [43]–[61]. BP, breakpoint; Inh_M, inherited by mother; Inh_F, inherited by father; AS, Angelman syndrome; ASD, Autism spectrum disorders; ADHD, attention deficit-hyperactivity disorder; BP, bipolar disorder; DD: developmental delay; DBD, disruptive behavior disorder; EPI, epilepsy; GAD, generalized anxiety disorder; OCD, obsessive-compulsive disorder; ID, intellectual disability; PWS, Prader-Willi syndrome; SCZ, schizophrenia.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 1 Not valid · 18 Not checked · 98 Own results and interpretations

61 more claims

Create a free account to see all 124 claims and to verify the 27 references still open.

See all claims — free account
  • It may state two separate claims as one. 34
  • Probably not a substantial claim. 35

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 91 references

Research works printed but not linked: 1

  1. 2008, Rare chromosomal deletions and duplications increase risk of schizophrenia., Nature, 455, 237, 10.1038/nature07239 · DOI · Paper page

Cited by

See all 449

Metadata

Authors
Leblond, C. S., Heinrich, J., Delorme, R., Proepper, C., Betancur, C., Huguet, G., Konyukh, M., Chaste, P., Ey, E., Rastam, M., Anckarsäter, H., Nygren, G., Gillberg, I. C., Melke, J., Toro, R., Regnault, B., Fauchereau, F., Mercati, O., Lemière, N., Skuse, D., Poot, M., Holt, R., Monaco, A. P., Järvelä, I., Kantojärvi, K., Vanhala, R., Curran, S., Collier, D. A., Bolton, P., Chiocchetti, A., Klauck, S. M., Poustka, F., Freitag, C. M., Waltes, R., Kopp, M., Duketis, E., Bacchelli, E., Minopoli, F., Ruta, L., Battaglia, A., Mazzone, L., Maestrini, E., Sequeira, A. F., Oliveira, B., Vicente, A., Oliveira, G., Pinto, D., Scherer, S. W., Zelenika, D., Delepine, M., Lathrop, M., Bonneau, D., Guinchat, V., Devillard, F., Assouline, B., Mouren, M.-C., Leboyer, M., Gillberg, C., Boeckers, T. M., & Bourgeron, T.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Universität Ulm (DE)
  • Lund University (SE)
  • University of Gothenburg (SE)
  • University College London (GB)
  • University Medical Center Utrecht (NL)
  • Centre for Human Genetics (GB)
  • University of Helsinki (FI)
  • King's College London (GB)
  • German Cancer Research Center (DE)
  • Goethe University Frankfurt (DE)
  • University of Bologna (IT)
  • University of Catania (IT)
  • University of Lisbon (PT)
  • University of Coimbra (PT)
  • Hospital for Sick Children (CA)
  • Hôpital Couple Enfant (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Inserm (FR)
Corresponding author
Bourgeron, Thomas
Venue
PLoS Genetics
Published
2012-02-09
Volume
8
Issue
2
Pages
e1002521
ISSN
  • 1553-7390 (ISSN-L)
  • 1553-7404
OpenAlex
W2123194540
Cited by
429
References
91
Citations by year
2026: 8 · 2025: 9 · 2024: 31 · 2023: 16 · 2022: 19 · 2021: 28 · 2020: 25 · 2019: 16 · 2018: 28 · 2017: 32 · 2016: 30 · 2015: 52 · 2014: 54 · 2013: 56 · 2012: 24
FWCI
35.74
Type
journal article
Language
en
Open access
Locations
  • PLoS Genetics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • HAL (submittedVersion, other-oa)
  • Research Portal (King's College London) (submittedVersion, other-oa)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
  • Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Funders
  • GlaxoSmithKline
  • Wellcome Trust (075491, 075491/Z/04,, 090532)
  • Fondation Orange
  • National Institute for Health and Care Research (NF-SI-0510-10268)
  • Deutsche Forschungsgemeinschaft
  • Agence Nationale de la Recherche (ANR-08-MNPS-0037)
  • Institut National de la Santé et de la Recherche Médicale
  • University of Toronto
  • Hospital for Sick Children
  • Hersenstichting
  • Assistance publique-Hôpitaux de Paris
  • Canadian Institutes of Health Research (213997)
  • NIH Clinical Center
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
Keywords
autism spectrum disorder, Shank2, de novo deletion, multiple-hit model, synaptic dysfunction, synaptic density, copy number variation, 15q11-q13, genetic modifiers, rare variants, conserved residues, neurodevelopmental disorders
MeSH terms
Adult, Cell Line, Child, Child Development Disorders, Pervasive, Child, Preschool, Female, Gene Expression Regulation, Humans, Male, Nerve Tissue Proteins, Neurons, Receptors, Nicotinic, Synapses, Tissue Distribution, Sequence Deletion, Alternative Splicing, Gene Dosage, Protein Isoforms, RNA Splice Sites, Adaptor Proteins, Signal Transducing, alpha7 Nicotinic Acetylcholine Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic and Functional Analyses of SHANK2 Mutations Suggest a Multiple Hit Model of Autism Spectrum Disorders. https://app.cochat.ai/papers/10.1371/journal.pgen.1002521
The paper
Leblond, C. S., Heinrich, J., Delorme, R., Proepper, C., Betancur, C., Huguet, G., Konyukh, M., Chaste, P., Ey, E., Rastam, M., Anckarsäter, H., Nygren, G., Gillberg, I. C., Melke, J., Toro, R., Regnault, B., Fauchereau, F., Mercati, O., Lemière, N., . . . Bourgeron, T. (2012). Genetic and Functional Analyses of SHANK2 Mutations Suggest a Multiple Hit Model of Autism Spectrum Disorders. PLoS Genetics. https://doi.org/10.1371/journal.pgen.1002521

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.